Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.

Journal of medicinal chemistry - 4 Nov 1999

Hopkins A L, Ren J, Tanaka H, Baba M, Okamato M, Stuart D I, Stammers D K

Abstract excerpt

Two analogues of the nonnucleoside inhibitor of HIV-1 RT, MKC-442 (emivirine), containing different C6 substituents have been designed to be less susceptible to the commonly found drug-resistance mutation of Tyr181Cys. Compound TNK-6123 had a C6 thiocyclohexyl group designed to have more flexibility in adapting to the mutated drug-binding site. GCA-186 had additional 3',5'-dimethyl substituents aimed at forming...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Drug Resistance, Microbial

Share to Molecular Conformation

Share to Reverse Transcriptase Inhibitors

Share to Uracil

Source

Identifiers

PMID: 10579814
DOI: 10.1021/jm990192c

Genes

GCA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.PMID 10579814Read ↗

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.Semantic proximity Read ↗

Discovery of 2,4,5-Trisubstituted 6-Aminopyrimidines as Potent HIV-1 NNRTIs with Improved Resistance Profiles against the K103N/Y181C MutantSemantic proximity Read ↗

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.Semantic proximity Read ↗

In silico structure-based design of a potent, mutation resilient, small peptide inhibitor of HIV-1 reverse transcriptase.Semantic proximity Read ↗

Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.Semantic proximity Read ↗

Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase.Semantic proximity Read ↗

Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallographySemantic proximity Read ↗

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.Semantic proximity Read ↗

Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.Semantic proximity Read ↗

Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse TranscriptaseSemantic proximity Read ↗

Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.Semantic proximity Read ↗

Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.